| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| vx-745 | stress-activated protein kinase 2b | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
0.94 | phase 2 | unknown |
| vx-745 | map kinase p38 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
0.49 | phase 2 | unknown |
| vx-745 | stress-activated protein kinase 2a | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
1.2 | phase 2 | inhibitor |
| vx-745 | stress-activated protein kinase 2a | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
1.2 | phase 2 | unknown |
| click here to return to the previous page | ||||||||